

Medexus Pharmaceuticals Inc

09:30 09 Jul 2020

Medexus says joint-disease drug added to public drug plans in four Canadian provinces

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) announced Thursday that its joint-disease drug Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been added to public drug plans in four Canadian provinces.

The drug has been approved for inclusion on the Alberta Drug Benefit List (ADBL), the Saskatchewan Drug Plan, the Newfoundland and Labrador Prescription Drug Program (NLPDP), and the Yukon Drug Formulary for the treatment of Juvenile Idiopathic Arthritis (JIA).

Also for public reimbursement, TH has been approved for inclusion on the Ontario Drug Benefit Formulary/Comparative Drug Index and the Non-Insured Health Benefits - Drug Benefit List for its full Health Canada-approved indication, which includes approved use in both adults and adolescents.

READ: Medexus fiscal 4Q revenue soars following IXINITY hemophilia drug acquisition

TH is the longest acting corticosteroid for intra-articular injection, often lasting twice as long as comparator products, the company said.

"The inclusion of our TH on these public drug plan formularies in Canada enhances the accessibility of this therapy for pediatric and adult patients suffering from chronic inflammatory diseases including JIA and RA (rheumatoid arthritis)," said Ken d'Entremont, Medexus CEO, in a statement.

"Previously, both younger and adult patients with subacute and chronic inflammatory joint diseases have had difficulty getting TH due to a long-standing shortage of Triamcinolone Hexacetonide in Canada."

He also noted that the company is advancing the commercial rollout of TH in additional provinces.

"Moreover, we believe our formulation has the potential to become the standard of care for the treatment of many severe joint diseases, as it significantly impacts the safety and cost-effectiveness of treatment by providing longer duration of action, with fewer injections, compared to other corticosteroid injections and intra-articular steroids," d'Entremont added.


Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 4.33

Market Cap: \$62.59 m

1 Year Share Price Graph



September 2019 March 2020 September 2020

Share Information

Code: MDP

Listing: TSX-V

52 week	High	Low
	4.49	1.42

Sector: Pharma & Biotech

Website: www.medexusinc.com

Company Synopsis:

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology and allergy.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).